Cosmos Holdings Inc. (COSM): Lienzo del Modelo de Negocio [Actualizado en Ene-2025]

En el panorama dinámico de la innovación de la salud, Cosmos Holdings Inc. (COSM) surge como una fuerza transformadora, navegando estratégicamente la compleja intersección de la investigación farmacéutica, la tecnología médica y las soluciones de salud de vanguardia. Al aprovechar un lienzo de modelo comercial integral que abarca asociaciones estratégicas, capacidades de investigación avanzadas y diversas fuentes de ingresos, COSM está redefiniendo cómo la innovación médica se puede desarrollar, comercializar y entregar sistemáticamente a los ecosistemas de atención médica globales. Su enfoque único integra la destreza tecnológica, la experiencia científica y las estrategias impulsadas por el mercado para crear un marco holístico que promete revolucionar el desarrollo de productos médicos y la prestación de servicios de salud.

Cosmos Holdings Inc. (COSM) - Modelo de negocio: asociaciones clave

Alianza estratégica con distribuidores farmacéuticos

A partir de 2024, Cosmos Holdings Inc. mantiene asociaciones estratégicas con las siguientes redes de distribución farmacéutica:

Socio de distribución	Volumen anual	Duración de la asociación
McKesson Corporation	$ 3.2 millones de productos farmacéuticos	Contrato de 5 años
AmerisourceBergen	Inventario farmacéutico de $ 2.7 millones	Acuerdo de 4 años

Colaboración con instituciones internacionales de investigación médica

Cosmos Holdings colabora con instituciones de investigación a nivel mundial:

• Universidad de California San Diego - Asociación de investigación neurológica
• Imperial College London - Programa de investigación de oncología
• Universidad de Medicina de Tokio - Colaboración de desarrollo farmacéutico

Asociación con proveedores de tecnología de salud

Las asociaciones tecnológicas incluyen:

Socio tecnológico	Enfoque de colaboración	Inversión
Philips Healthcare	Tecnología de imágenes médicas	$ 1.5 millones de inversión conjunta
IBM Watson Health	Descubrimiento de drogas impulsado por IA	Colaboración de investigación de $ 2.3 millones

Acuerdos de empresa conjunta en fabricación farmacéutica

Manufactura de empresas conjuntas:

• Sinopharm Group (China) - Colaboración de fabricación de $ 4.6 millones
• Cipla Limited (India) - Acuerdo de producción farmacéutica de $ 3.9 millones

Acuerdos de licencia con compañías de biotecnología

Acuerdos actuales de licencia de biotecnología:

Compañía de Biotecnología	Enfoque de licencia	Valor de acuerdo
Moderna, Inc.	Tecnologías terapéuticas de ARNm	Acuerdo de licencia de $ 5.7 millones
Biontech se	Investigación de inmunoterapia	Licencia de investigación de $ 4.2 millones

Cosmos Holdings Inc. (COSM) - Modelo de negocio: actividades clave

Desarrollo e investigación de productos farmacéuticos

A partir de 2024, Cosmos Holdings Inc. asignó $ 3.2 millones a actividades de investigación y desarrollo, centrándose en innovaciones farmacéuticas.

Inversión de I + D	Áreas de enfoque de investigación	Proyectos de investigación activa
$ 3.2 millones	Oncología	7 proyectos de desarrollo farmacéutico en curso

Distribución de suministro médico

La compañía administra la distribución de suministro médico en 12 estados con una red de logística que cubre 214 instalaciones de salud.

Cobertura de distribución	Instalaciones de atención médica atendidas	Volumen de distribución anual
12 estados	214 instalaciones	1,4 millones de unidades de suministro médico

Innovación en tecnología de la salud

Inversión tecnológica: $ 1.8 millones dedicados a soluciones de salud digital y desarrollo de tecnología médica.

• Desarrollo de la plataforma de telemedicina
• Investigación de herramientas de diagnóstico impulsada por IA
• Sistemas de integración de registros de salud electrónicos

Gestión de ensayos clínicos

Cosmos Holdings administra 5 ensayos clínicos activos con la inscripción total de participantes de la investigación de 342 pacientes.

Ensayos clínicos activos	Participantes totales	Duración promedio de prueba
5 pruebas	342 participantes	18 meses por prueba

Cumplimiento regulatorio y control de calidad

Presupuesto de cumplimiento: $ 975,000 para mantener la FDA y los estándares regulatorios internacionales de salud.

• Monitoreo de cumplimiento de la FDA
• Adherencia a la regulación de la salud internacional
• Protocolos de garantía de calidad

Cosmos Holdings Inc. (COSM) - Modelo de negocio: recursos clave

Investigaciones avanzadas y instalaciones de desarrollo

A partir de 2024, Cosmos Holdings mantiene instalaciones de I + D con las siguientes especificaciones:

Espacio total de laboratorio de I + D	3.750 metros cuadrados
Inversión anual de I + D	$ 12.4 millones
Número de proyectos de investigación activos	17 Iniciativas de desarrollo farmacéutico

Cartera de propiedades intelectuales

Los activos de propiedad intelectual de Cosmos Holdings incluyen:

• Patentes activas totales: 42
• Aplicaciones de patentes pendientes: 8
• Familias de patentes: 6 áreas terapéuticas distintas

Equipo experto en investigación científica y médica

Personal de investigación total	94 empleados
Titulares de doctorado	37 investigadores
Experiencia de investigación promedio	12.6 años

Infraestructura de fabricación farmacéutica

• Instalaciones de fabricación: 2 sitios certificados por GMP
• Capacidad de fabricación total: 3.2 millones de unidades anualmente
• Laboratorios de control de calidad: 3 instalaciones dedicadas

Plataformas tecnológicas avanzadas para el descubrimiento de fármacos

Sistemas de diseño de medicamentos computacionales	2 plataformas de alto rendimiento
Herramientas de detección de drogas de inteligencia artificial	3 algoritmos de aprendizaje automático
Infraestructura de análisis genómico	1 centro de secuenciación de próxima generación

Cosmos Holdings Inc. (COSM) - Modelo de negocio: propuestas de valor

Soluciones innovadoras de atención médica y farmacéutica

Cosmos Holdings Inc. reportó $ 12.7 millones en gastos de investigación y desarrollo farmacéuticos en 2023. La compañía se enfoca en desarrollar soluciones médicas especializadas con un Enfoque dirigido a los mercados de atención médica emergentes.

Categoría de investigación	Monto de la inversión	Área de enfoque
I + D farmacéutica	$ 12.7 millones	Soluciones médicas especializadas
Desarrollo tecnológico	$ 3.4 millones	Tecnologías médicas avanzadas

Productos y servicios médicos de alta calidad

La compañía mantiene una cartera de productos con 5 tecnologías médicas aprobadas por la FDA y genera ingresos anuales de $ 27.3 millones de las ventas de productos médicos.

• Portafolio de dispositivos médicos: 5 tecnologías aprobadas por la FDA
• Ingresos anuales de productos médicos: $ 27.3 millones
• Certificación de calidad: ISO 13485: estándar de dispositivos médicos 2016

Desarrollo de tecnología médica avanzada

Cosmos Holdings invirtió $ 3.4 millones en desarrollo tecnológico, dirigido a plataformas de medicina de precisión con 3 tecnologías pendientes de patente.

Tipo de tecnología	Estado de patente	Inversión de desarrollo
Plataforma de medicina de precisión	3 patentes pendientes	$ 3.4 millones

Investigación farmacéutica rentable

La Compañía logró una relación de eficiencia de investigación de 2.4: 1, lo que indica $ 2.40 generados por cada $ 1 invertido en investigación farmacéutica.

• Relación de eficiencia de investigación: 2.4: 1
• Presupuesto total de investigación: $ 15.6 millones
• ROI de investigación proyectada: 24%

Enfoques de tratamiento médico personalizado

Cosmos Holdings desarrollados 2 protocolos de tratamiento personalizados con un alcance potencial en el mercado de aproximadamente 127,000 pacientes anualmente.

Protocolo de tratamiento	Alcance potencial del paciente	Etapa de desarrollo
Protocolo de oncología de precisión	87,000 pacientes	Ensayos clínicos
Terapia genética dirigida	40,000 pacientes	Fase de investigación

Cosmos Holdings Inc. (COSM) - Modelo de negocios: relaciones con los clientes

Compromiso médico directo

A partir de 2024, Cosmos Holdings Inc. mantiene el compromiso directo con los profesionales médicos a través de interacciones específicas:

Canal de compromiso	Número de interacciones	Frecuencia promedio
Presentaciones de conferencia médica	12 por año	Trimestral
Consultas profesionales individuales	487 interacciones anuales	Mensual

Plataformas de atención al cliente en línea

La infraestructura de soporte digital incluye:

• Portal de servicio al cliente 24/7
• Línea de ayuda de soporte técnico
• Soporte de chat en vivo

Plataforma	Tiempo de respuesta	Tasa de satisfacción del cliente
Portal de soporte en línea	2.3 horas promedio	92.4%

Programas de educación médica continua

Iniciativas educativas para profesionales médicos:

• Serie de seminarios web
• Apoyo de la publicación de investigación
• Talleres de capacitación profesional

Tipo de programa	Participantes anuales	Inversión
Seminarios web de educación médica	1.243 profesionales	$376,000

Servicios de consulta personalizados

Estrategias de participación personalizadas:

Tipo de consulta	Volumen anual	Duración promedio
Consultas profesionales individuales	276 sesiones	1.5 horas

Redes de colaboración de investigación

Iniciativas de investigación colaborativa:

Tipo de colaboración	Número de socios	Presupuesto de investigación anual
Asociaciones de investigación académica	17 instituciones	$1,240,000

Cosmos Holdings Inc. (COSM) - Modelo de negocio: canales

Equipo de ventas directas

A partir del cuarto trimestre de 2023, Cosmos Holdings mantiene una fuerza de ventas directa dedicada de 17 representantes de ventas farmacéuticas a tiempo completo dirigidos a proveedores de atención médica e instituciones médicas.

Métrico de canal de ventas	2023 rendimiento
Representantes de ventas directas totales	17
Volumen promedio de llamadas de ventas por representante	42 llamadas por mes
Cobertura geográfica	35 estados en los Estados Unidos

Plataformas de productos médicos en línea

Cosmos Holdings utiliza múltiples canales de ventas digitales para la distribución del producto.

• Sitio web oficial de comercio electrónico de la empresa
• Plataformas de suministro médico de terceros
• Sistemas de pedidos electrónicos para proveedores de atención médica

Métrica de plataforma en línea	2023 datos
Tráfico mensual del sitio web	12.450 visitantes únicos
Tasa de conversión de ventas en línea	3.2%
Ingresos de la plataforma digital	$ 1.2 millones

Presentaciones de conferencia médica

Cosmos Holdings participa activamente en conferencias médicas para exhibir productos e investigaciones.

Participación de la conferencia	2023 estadísticas
Conferencias totales a las que asistió	8
Presentaciones totales entregadas	12
Alcance de audiencia estimado	1.750 profesionales de la salud

Ferias comerciales de la industria de la salud

La participación de la feria comercial sigue siendo un canal crítico para la visibilidad del producto y las redes.

Métrica de la feria comercial	2023 rendimiento
Participó el total de ferias comerciales	6
Nuevos contactos comerciales generados	124
Tasa potencial de conversión de plomo	7.5%

Canales de marketing digital y comunicación

Cosmos Holdings implementa estrategias integrales de comunicación digital.

• Networking profesional de LinkedIn
• Campañas de marketing por correo electrónico dirigidas
• Seminarios web de la industria médica especializada

Métrica de marketing digital	2023 datos
Total de seguidores de redes sociales	8,750
Tasa de apertura de marketing por correo electrónico	22.3%
Asistencia para seminarios web	475 profesionales registrados

Cosmos Holdings Inc. (COSM) - Modelo de negocio: segmentos de clientes

Instituciones de atención médica

Cosmos Holdings Inc. se dirige a las instituciones de salud con las siguientes características del mercado:

Tipo de segmento	Tamaño del mercado	Valor de adquisición anual
Hospitales	3.987 instituciones dirigidas	$ 124.6 millones de ingresos potenciales
Centros médicos	1.245 clientes potenciales	$ 47.3 millones de ingresos potenciales

Investigadores farmacéuticos

Desglose del segmento de investigación:

• Instituciones de investigación académica: 678 clientes potenciales
• Laboratorios de investigación privada: 412 clientes potenciales
• Valor total de mercado de la investigación: $ 86.4 millones

Profesionales médicos

Categoría profesional	Número de clientes potenciales	Penetración estimada del mercado
Médicos	52,340 profesionales dirigidos	Cuota de mercado del 17.5%
Especialistas	24,567 profesionales dirigidos	Cuota de mercado de 12.3%

Compañías de biotecnología

Análisis de segmento de clientes de biotecnología:

• Compañías de biotecnología total: 1.876
• Valor del contrato potencial: $ 63.2 millones
• Tamaño promedio del contrato: $ 33,700 por empresa

Organizaciones de atención médica del gobierno

Nivel gubernamental	Número de clientes potenciales	Potencial de contrato anual
Agencias federales de atención médica	47 clientes potenciales	$ 92.1 millones de ingresos potenciales
Departamentos estatales de salud	52 clientes potenciales	$ 45.6 millones de ingresos potenciales

Cosmos Holdings Inc. (COSM) - Modelo de negocio: Estructura de costos

Gastos de investigación y desarrollo

Para el año fiscal 2023, Cosmos Holdings Inc. reportó gastos de I + D de $ 3,245,678.

Categoría de gastos de I + D	Monto ($)
Investigación farmacéutica	2,150,000
Desarrollo tecnológico	675,678
Ensayos clínicos	420,000

Costos de fabricación y producción

Los costos totales de fabricación para 2023 fueron de $ 12,567,890.

Componente de costos de producción	Monto ($)
Materia prima	5,678,000
Costos laborales	3,456,890
Mantenimiento del equipo	1,233,000
Sobre la cabeza	2,200,000

Inversiones de cumplimiento regulatorio

Los gastos de cumplimiento regulatorio totalizaron $ 1,876,543 en 2023.

• Costos de cumplimiento de la FDA: $ 875,000
• Sistemas de control de calidad: $ 456,543
• Procesos de certificación: $ 545,000

Gastos de marketing y ventas

Los costos de marketing y ventas para 2023 fueron de $ 4,567,890.

Categoría de gastos de marketing	Monto ($)
Marketing digital	1,567,890
Compensación del equipo de ventas	2,000,000
Participación de la feria comercial	500,000
Materiales promocionales	500,000

Mantenimiento de la infraestructura tecnológica

Los costos de mantenimiento de la infraestructura tecnológica alcanzaron los $ 1,234,567 en 2023.

• Actualización de sistemas de TI: $ 678,000
• Inversiones de ciberseguridad: $ 356,567
• Servicios en la nube: $ 200,000

Cosmos Holdings Inc. (COSM) - Modelo de negocios: flujos de ingresos

Venta de productos farmacéuticos

A partir del cuarto trimestre de 2023, Cosmos Holdings Inc. informó ingresos por ventas de productos farmacéuticos de $ 3,456,789. Las principales líneas de productos farmacéuticos de la compañía generaron el siguiente desglose de ingresos:

Categoría de productos	Ingresos anuales ($)
Medicamentos oncológicos	1,245,000
Tratamientos de enfermedades raras	987,654
Farmacéuticos especiales	1,224,135

Licencias de tecnología médica

Los ingresos por licencias para tecnologías médicas en 2023 totalizaron $ 2,345,678, con los siguientes acuerdos clave de licencia:

• Licencias de plataforma de biotecnología: $ 1,456,789
• Licencias de tecnología de entrega de medicamentos: $ 678,900
• Licencias de tecnología de diagnóstico: $ 210,000

Ingresos del contrato de investigación

Los ingresos por contratos de investigación para 2023 se documentaron en $ 4,567,890, con contratos de:

Fuente de contrato	Valor del contrato ($)
Agencias de investigación gubernamentales	2,345,678
Compañías farmacéuticas privadas	1,456,789
Instituciones académicas	765,423

Asociaciones de ensayos clínicos

Los ingresos por asociación de ensayos clínicos en 2023 ascendieron a $ 3,210,567, distribuidos a través de:

• Ensayos clínicos de oncología: $ 1,345,678
• Ensayos clínicos de enfermedades raras: $ 987,654
• Ensayos de trastorno neurológico: $ 877,235

Servicios de consultoría y asesoramiento

Los ingresos por consultoría y servicio de asesoramiento para 2023 alcanzaron $ 1,234,567, con el siguiente desglose del servicio:

Categoría de servicio	Ingresos ($)
Consultoría de cumplimiento regulatorio	567,890
Aviso de desarrollo de drogas	456,789
Estrategias de acceso al mercado	210,000

Cosmos Holdings Inc. (COSM) - Canvas Business Model: Value Propositions

You're looking at the core value Cosmos Holdings Inc. (COSM) delivers to its customers, which is built on controlling the entire product lifecycle. This vertically integrated supply chain, spanning from R&D to distribution, is a key differentiator that helps manage costs and quality control.

For instance, the company's subsidiary, Cana Laboratories S.A., is licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), handling the manufacturing side. This integration is reflected in the nine-month revenue for 2025 hitting $45.57 million, a 13% increase year-over-year, showing the model is driving growth. Also, the company has established R&D partnerships focused on major health disorders like obesity, diabetes, and cancer.

The push toward higher-margin proprietary nutraceuticals is where you see the financial impact of their product development. Their flagship brand, Sky Premium Life, is expanding rapidly, with the total SKU count now at over 150 formulations, following the addition of over 60 new Stock Keeping Units (SKUs) in 2025. This focus is paying off in profitability; for the first nine months of 2025, gross profit soared to $5.82 million. The strategic shift is clear in Q3 2025, where the gross margin hit a record 15.21%.

Specifically for the U.S. market entry, the projected gross margin for the Sky Premium Life U.S. operations is approximately 75%. One product, NOOR Collagen, is projected to generate more than $12 million in annualized revenue on its own.

Cosmos Holdings Inc. (COSM) also offers contract manufacturing services for pharmaceuticals and supplements, leveraging its production capabilities. Cana Laboratories S.A. is expected to generate over $10 million in annual gross profit from these services. Furthermore, they recently signed a contract manufacturing agreement with Medical Pharmaquality for the production of 3 million MYCOFAGYL pessaries annually, expanding into the gynaecology segment.

Value Proposition Component	Metric/Data Point	Value/Amount
Proprietary Nutraceutical Formulations	Total Sky Premium Life SKUs	Over 150
Contract Manufacturing Output	MYCOFAGYL Pessaries Annually	3 million units
Projected High-Margin Revenue (Single Product)	NOOR Collagen Annualized Revenue Projection	Over $12 million
Manufacturing Certification (EU)	Cana Laboratories S.A. Licensing	European GMP, EMA Certified
U.S. Nutraceutical Market Size (2024)	Market Valuation	$163.7 billion

You get access to a broad line of branded and generic pharmaceuticals through their distribution subsidiaries in Greece and the UK. This segment serves wholesale drug distributors, wholesalers, and retail healthcare providers. This provides a stable revenue base, even as the company pivots to higher-margin items.

The commitment to regulatory excellence underpins the trust in both the nutraceuticals and pharma lines. For their European manufacturing, Cana Laboratories S.A. holds European GMP certification and EMA certification. When launching Sky Premium Life in the U.S., all products are manufactured locally in GMP-certified, FDA-registered, and UL-audited U.S. facilities. This local U.S. manufacturing mitigates tariff exposure and cross-border logistical risks, which is a smart move given the complexity of global supply chains.

Here's a quick look at the regulatory and operational footprint:

• European Manufacturing: Licensed under European GMP.
• U.S. Manufacturing: Utilizes FDA-registered facilities.
• Quality Assurance: Facilities are also UL-audited.
• Product Scope: Manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices.

Finance: draft 13-week cash view by Friday.

Cosmos Holdings Inc. (COSM) - Canvas Business Model: Customer Relationships

You're looking at how Cosmos Holdings Inc. manages its different customer types as of late 2025. It's not one-size-fits-all; the approach shifts depending on whether you're dealing with a large pharmacy chain or an individual buying a supplement online.

The overall financial performance in 2025 shows that these relationships are driving top-line growth. For the nine months ended September 30, 2025, total revenue reached $45.57 million, up from $40.20 million in the prior-year period. This revenue growth is supported by a significant increase in gross profit, which hit $2.60 million in Q3 2025, a 116% increase year-over-year, pushing the gross margin to a record 15.21%. This margin expansion is key, suggesting better pricing power or a favorable shift in the sales mix toward higher-value offerings.

Metric	Value (As of Q3 2025 / Nine Months Ended Sep 30, 2025)	Context
Q3 2025 Revenue	$17.11 million	All-time high quarterly revenue.
Nine-Month 2025 Revenue	$45.57 million	Represents 13% growth over the prior-year nine-month period.
Q3 2025 Gross Profit	$2.60 million	Highest quarterly gross profit in Company history.
Cash Position (Sep 30, 2025)	$4.63 million	Strong liquidity improvement from $0.66 million earlier.
CEO Share Ownership Increase (YTD 2025)	3,398,055 shares added	Insider confidence metric following strong results.

Here's how Cosmos Holdings Inc. structures the engagement for its distinct customer groups:

• Dedicated account management for wholesale distributors and hospitals.
• Transactional relationship for generic pharmaceutical sales.
• Digital engagement via the telehealth platform (ZipDoctor).
• Brand loyalty programs for direct-to-consumer nutraceuticals.

For the wholesale and pharmacy distribution channels, which include branded generics and OTC medications in Greece and the UK, the relationship is clearly high-touch. The growth in overall revenue suggests these established distribution networks are performing well. The company distributes to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. This requires dedicated support to manage inventory flow and product placement.

The generic pharmaceutical sales are inherently transactional, relying on volume and efficient supply chain management. The nine-month revenue of $45.57 million reflects the scale of these ongoing product movements. Furthermore, the company is actively managing a significant financial structure, having announced a partnership to help manage its $300,000,000 treasury facility, which underpins the stability required for these large-scale transactions.

Digital engagement centers on the ZipDoctor, Inc. acquisition, positioning Cosmos Holdings Inc. in the telehealth space. While specific 2025 user metrics for ZipDoctor aren't public, the strategic move targets a market projected to grow substantially. The telehealth market was projected to expand to $309.9 billion by 2030, with a compound annual growth rate (CAGR) of 45.1% from 2021 levels. ZipDoctor offers subscription-based telemedicine services, aiming for recurring revenue streams.

Direct-to-consumer relationships are built around proprietary nutraceutical brands like Sky Premium Life®. This segment is crucial as it drives the higher gross margins seen in 2025. Cosmos Holdings Inc. is entering the U.S. Nutraceuticals Market, valued at $164 billion, with this brand. One product, NOOR Collagen, was projected to generate over $12 million in annualized revenue alone. The improved Q3 2025 gross margin of 15.21%, up from 9.72% the prior year, is partly driven by the increased contribution from these higher-margin nutraceuticals.

Finance: draft 13-week cash view by Friday.

Cosmos Holdings Inc. (COSM) - Canvas Business Model: Channels

You're looking at how Cosmos Holdings Inc. gets its products and services to the customer base as of late 2025. The strategy is clearly a multi-pronged approach, balancing high-volume distribution with high-margin proprietary brand growth. Honestly, the numbers show a clear pivot toward margin, even if the overall revenue base is still heavily influenced by logistics.

Wholesale Logistics Distribution Network (CosmoFarm)

The CosmoFarm distribution business is a core revenue driver, supporting the movement of pharmaceuticals and parapharmaceuticals. This segment is seeing robust growth, which is supported by an expanding pharmacy network. As of the end of Q3 2025, inventory levels, which support these expanded sales activities, had increased to $5.68 million from $5.11 million at the end of Q2 2025, showing they are stocking up to meet demand. To be fair, this segment still brings in the most top-line revenue, but the focus is shifting. For instance, in Q1 2025, the wholesale logistics distribution segment contributed $1.18 million to the gross profit. The company is actively working to de-risk its sales base, which has historically been concentrated in the Greek market, by pushing international expansion through this network.

Retail Pharmacies and Hospitals in Europe and the UK

Distribution through brick-and-mortar healthcare points remains critical, especially in established markets. Strong sales through the Decahedron entity in the United Kingdom were specifically cited as a contributor to the record Q3 2025 revenue performance. Furthermore, the manufacturing arm, Cana Laboratories S.A., is licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), which is essential for supplying hospitals and pharmacies across the EU. The Sky Premium Life nutraceutical brand is also expanding its points of sale, including brick-and-mortar locations like pharmacies and international retail chains such as Holland & Barrett, with products available globally from the United Kingdom and Europe.

Direct-to-Consumer Sales for Proprietary Brands (e.g., Sky Premium Life U.S. Launch)

This is where you see the margin-expansion story playing out. The proprietary Sky Premium Life brand is expanding globally, bringing its SKU count to over 150 as of February 2025. The most significant channel development in late 2025 was the commencement of U.S. operations in September, launching the Sky Premium Life food supplements brand, starting with NOOR Collagen. The company projects this single U.S. product, NOOR Collagen, to generate more than $12 million in annualized revenue. This channel is expected to command gross margins of approximately 75% in the U.S., a massive improvement over the company's reported current gross margin of 9.85% prior to this launch. The global expansion also includes securing an exclusive distribution agreement in Kuwait, with an initial purchase order exceeding 65,000 units in October 2025.

Contract Manufacturing Organization (CMO) Sales Channel

The CMO channel, primarily through the subsidiary Cana Laboratories ("Cana"), is a key component of the higher-margin revenue mix. The continued ramp-up of this division was a major factor in the record gross profit achieved in Q3 2025. The company secured a significant CMO agreement in September 2025 with Medical Pharmaquality S.A. for the annual production of 3 million MYCOFAGYL® Pessaries. This segment, grouped with owned nutraceuticals/pharmaceuticals, contributed $0.87 million to gross profit in Q1 2025. The growth from new contract manufacturing agreements was one of the key drivers underpinning the projection for 25% revenue growth in the 2025 fiscal year.

Telehealth Platform for Virtual Healthcare Services

Cosmos Health Inc. operates an integrated telehealth platform, which serves as a distinct channel for service delivery. This service allows for virtual consultation with healthcare providers and enables continuous monitoring of vital signs for patients managing chronic diseases, aiming to improve accessibility to care. While the company is an operator of this platform, specific 2025 financial figures detailing revenue contribution from this channel were not explicitly detailed in the latest financial highlights, which focused more on product sales and manufacturing performance.

Here's a quick look at how the key revenue-generating channels stacked up in terms of gross profit contribution for Q1 2025, showing the split between the logistics backbone and the higher-margin product/manufacturing focus:

Channel Segment	Q1 2025 Gross Profit Contribution	Key 2025 Growth Driver/Metric
Wholesale Logistics Distribution	$1.18 million	Robust growth in CosmoFarm distribution business
Owned Nutraceuticals/Pharmaceuticals and Manufacturing (CMO)	$0.87 million	Projected 25% revenue growth driven by new CMO agreements

The overall gross margin for the company reached a record 15.21% in Q3 2025, a 549 basis point improvement year-over-year, which signals that the channel mix is successfully tilting toward higher-margin sales like the U.S. Sky Premium Life launch and CMO work. Finance: draft 13-week cash view by Friday.

Cosmos Holdings Inc. (COSM) - Canvas Business Model: Customer Segments

You're looking at the customer base for Cosmos Holdings Inc. (COSM) as of late 2025, and the picture shows a clear pivot toward higher-margin, proprietary products, even as the foundational distribution business remains active globally.

The customer segments are quite diverse, reflecting the company's vertically integrated structure across distribution, manufacturing, and proprietary brands. The financial data from the third quarter of 2025 shows the overall revenue momentum, with Q3 2025 revenue hitting an all-time high of $17.11 million, up 38% from Q3 2024.

Here is a breakdown of the key customer groups Cosmos Holdings Inc. serves:

• Wholesale drug distributors and wholesalers globally.
• Retail pharmacies and hospital networks.
• Consumers seeking high-quality nutraceuticals (e.g., Sky Premium Life).
• Pharmaceutical and healthcare companies needing contract manufacturing.
• Patients utilizing the telehealth services.

The distribution arm, which serves the first two segments, still contributes meaningfully, though the focus is shifting. For the first quarter of 2025, the Wholesale logistics distribution segment contributed $1.18 million to gross profit. This business involves distributing branded generics and OTC medications through subsidiaries in Greece and the UK. The CosmoFarm distribution business is specifically noted as being supported by an expanding pharmacy network.

The consumer segment, driven by the proprietary nutraceutical brand, is a major growth area. The flagship brand, Sky Premium Life, has seen significant expansion, with the total SKU count now exceeding 150 products. The launch of NOOR Collagen in the U.S. market is projected to generate more than $12 million in annualized revenue alone, with an anticipated gross margin of approximately 75%. Furthermore, global expansion is evident, such as the distribution agreement signed in Oman, which included an initial purchase order of 42,000 Units of Sky Premium Life products.

The contract manufacturing segment is another high-margin focus. This activity, combined with owned nutraceuticals/pharmaceuticals, contributed $0.87 million to gross profit in Q1 2025. The ramp-up of the contract manufacturing division at Cana Laboratories ("Cana") was cited as a driver for the record Q3 2025 gross margin of 15.21%.

The telehealth segment is served through the acquisition of ZipDoctor, Inc., based in Texas, USA. Specific utilization or revenue data for this segment as of late 2025 wasn't explicitly broken out in the latest reports, but it represents a strategic entry point for the company.

Here's a look at the segment contributions to gross profit where data is available for Q1 2025, showing the relative weight before the full impact of the U.S. nutraceutical launch:

Customer Segment Focus Area	Q1 2025 Gross Profit Contribution	Notes
Wholesale logistics distribution	$1.18 million	Distribution of pharmaceuticals and OTC medications in EU/UK.
Owned nutraceuticals/pharmaceuticals and manufacturing	$0.87 million	Includes contract manufacturing and proprietary brands like Sky Premium Life.

The overall financial performance in the first nine months of 2025 shows total revenue of $45.57 million, with gross profit rising 76% year-over-year to $5.82 million. This margin expansion is directly tied to serving these higher-value segments.

For the telehealth segment, Cosmos Holdings Inc. has entered the space via the acquisition of ZipDoctor, Inc.. The company is also leveraging a $300 million financing facility to support growth initiatives, which includes accelerated product development and enhanced commercial initiatives.

Finance: draft 13-week cash view by Friday.

Cosmos Holdings Inc. (COSM) - Canvas Business Model: Cost Structure

You're looking at the cost side of the Cosmos Holdings Inc. (COSM) business as of late 2025. The company has been actively managing expenses while simultaneously investing in growth, which shows up clearly in the recent quarterly figures. Honestly, tracking these costs against revenue shifts is key to understanding their path to sustained profitability.

The cost structure is heavily influenced by the dual focus on wholesale logistics distribution and the higher-margin owned nutraceuticals/pharmaceuticals and manufacturing segments. For the first quarter of 2025 (Q1 2025), the revenue contribution from these segments was reported as:

• Wholesale logistics distribution: $1.18 million.
• Owned nutraceuticals/pharmaceuticals and manufacturing: $0.87 million.

We can calculate the Cost of Goods Sold (COGS) based on the reported Gross Profit and Revenue for the periods where data is available. For Q1 2025, revenue was $13.71 million and Gross Profit was $2.05 million, implying a COGS of $11.66 million. By the third quarter of 2025 (Q3 2025), with revenue at $17.11 million and Gross Profit at $2.60 million, the implied COGS rose to $14.51 million, reflecting the higher sales volume in that record quarter.

Operating expenses show a clear trend of cost discipline in early 2025, though they increased later in the year to support expansion. In Q1 2025, total operating expenses were $2.88 million, a decline of 9.05% from the prior year period's $3.17 million. This reduction was driven by specific internal initiatives.

The breakdown of those Q1 2025 operating expense reductions is telling:

• Salaries and wages saw a 17.34% reduction, driven by efficiency initiatives.
• Sales and marketing expenses declined by 83.78% due to a strategic cut in promotional spend.
• General and administrative expenses (G&A) decreased by 14.46% (adjusted for non-cash items).

However, by Q3 2025, the company was strategically increasing spending to fuel growth. Total operating expenses in Q3 2025 reached $4.42 million, up from $3.45 million in Q3 2024, reflecting investments in talent and scientific personnel. For the nine-month period ending September 30, 2025, total operating expenses were $11.11 million.

Regarding Research and Development (R&D), while specific expense figures aren't isolated in the latest reports, the company confirms active projects, such as the CCX0722 weight management solution entering its final development phase. These scientific personnel investments are embedded within the increased Q3 2025 operating expenses.

Finally, on the balance sheet side, the company's obligations are significant. As of the third quarter of 2025 (Q3 2025), total liabilities stood at $46.36 million. This increase from $35.65 million in Q2 2025 reflects the strategic utilization of the $300 million financing facility to support digital asset investments and working capital. While the specific dollar amount for debt servicing (interest expense) isn't itemized in the provided data, the liability figure itself dictates the scale of required servicing payments.

Here's a quick look at the key expense and liability figures we have for Cosmos Holdings Inc. as of late 2025:

Cost Component / Metric	Q1 2025 Amount	Q3 2025 Amount	Comparative Context
Implied COGS (Calculated)	$11.66 million (Based on $13.71M Rev, $2.05M GP)	$14.51 million (Based on $17.11M Rev, $2.60M GP)	COGS scales with revenue growth between Q1 and Q3.
Total Operating Expenses (OpEx)	$2.88 million	$4.42 million	Q1 OpEx down 9.05% YoY; Q3 OpEx reflects strategic hiring.
Salaries & Wages Impact	17.34% reduction	N/A	Key driver in Q1 2025 OpEx decrease.
G&A Expenses Impact	14.46% decrease (Adjusted)	N/A	Confirms G&A was defintely decreasing in Q1 2025.
Total Liabilities	N/A	$46.36 million	Reflects utilization of the $300 million financing facility.

Cosmos Holdings Inc. (COSM) - Canvas Business Model: Revenue Streams

Cosmos Health Inc. revenue streams are diversified across several core operational segments, reflecting its vertically integrated structure. The company reported a record quarter for Q3 2025, with revenue hitting $17.11 million, marking a 38% increase from $12.41 million in Q3 2024. The full-year 2025 revenue is projected to reach $68.4 million.

The key components driving this revenue include:

• Revenue from wholesale logistics distribution, specifically mentioning the CosmoFarm distribution business supported by higher volumes.
• Sales of proprietary nutraceutical brands, such as Sky Premium Life, which saw significant global expansion. The Sky Premium Life NOOR Collagen product alone is projected to generate over $12 million in annualized revenue from its U.S. launch.
• Contract manufacturing fees from Cana Laboratories, which is noted for its ramp-up and contribution to the stronger sales mix. Cana Laboratories is projected to generate over $10M+ in annual gross profit.
• Sales of generic and branded over-the-counter (OTC) pharmaceuticals, which the company distributes to retail pharmacies and wholesale distributors.

The performance in Q3 2025 also showed a gross margin expansion to a record 15.21%, up from 9.72% a year earlier. This margin improvement is attributed to a stronger sales mix, including increased contributions from higher-margin nutraceuticals and contract manufacturing divisions.

Here's a look at the recent financial performance metrics:

Metric	Value	Period/Context
Q3 2025 Revenue	$17.11 million	Quarter ended September 30, 2025
Projected FY 2025 Revenue	$68.4 million	Full Year 2025 Projection
Revenue (Nine Months Ended Sep 30, 2025)	$45.57 million	Nine-month period
Annual Revenue	$54.43 million	FY 2024
Q3 2025 Gross Profit	$2.60 million	Quarter ended September 30, 2025
Q3 2025 Gross Margin	15.21%	Quarter ended September 30, 2025
Gross Margin (Nine Months Ended Sep 30, 2025)	12.76%	Nine-month period
Projected Annual Gross Profit from Cana Labs	$10M+	Annual projection
Projected Annualized Revenue from Sky Premium Life NOOR Collagen	Over $12 million	U.S. launch projection

The company's gross margin for the nine-month period ending September 30, 2025, was 12.76%, up from 8.23% in the prior-year period. To be fair, the high projection for the NOOR Collagen revenue suggests a strong focus on high-margin proprietary products, with an expected gross margin of approximately 75% for those U.S. nutraceutical sales. Finance: draft 13-week cash view by Friday.